Viridian Therapeutics
company
About
Viridian Therapeutics discovers and develops innovative microRNA-targeting therapies to improve human health.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $75M
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2007
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$79M
Viridian Therapeutics has raised a total of
$79M
in funding over 2 rounds. Their latest funding was raised on
Apr 4, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 4, 2022 | Post-IPO Debt | $75M | 1 |
Hercules Capital
|
— | Detail |
| Jun 3, 2009 | Series A | $4M | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
1
1
Viridian Therapeutics has made 1 investments. Their most recent investment was on
Sep 3, 2015, when Tala raised $10M.
Investors
Number of Lead Investors
Number of Investors
1
2
Viridian Therapeutics is funded by 2 investors.
Hercules Capital
and The Peierls Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
